132 related articles for article (PubMed ID: 16527257)
1. Catalytic roles of CYP2D6.10 and CYP2D6.36 enzymes in mexiletine metabolism: in vitro functional analysis of recombinant proteins expressed in Saccharomyces cerevisiae.
Hanioka N; Okumura Y; Saito Y; Hichiya H; Soyama A; Saito K; Ueno K; Sawada J; Narimatsu S
Biochem Pharmacol; 2006 Apr; 71(9):1386-95. PubMed ID: 16527257
[TBL] [Abstract][Full Text] [Related]
2. Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6.
Shimada T; Tsumura F; Yamazaki H; Guengerich FP; Inoue K
Pharmacogenetics; 2001 Mar; 11(2):143-56. PubMed ID: 11266079
[TBL] [Abstract][Full Text] [Related]
3. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
4. Inhibitory effects of psychotropic drugs on mexiletine metabolism in human liver microsomes: prediction of in vivo drug interactions.
Hara Y; Nakajima M; Miyamoto KI; Yokoi T
Xenobiotica; 2005 Jun; 35(6):549-60. PubMed ID: 16192107
[TBL] [Abstract][Full Text] [Related]
5. Involvement of CYP1A2 in mexiletine metabolism.
Nakajima M; Kobayashi K; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
Br J Clin Pharmacol; 1998 Jul; 46(1):55-62. PubMed ID: 9690950
[TBL] [Abstract][Full Text] [Related]
6. Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes.
Yamazaki H; Guo Z; Persmark M; Mimura M; Inoue K; Guengerich FP; Shimada T
Mol Pharmacol; 1994 Sep; 46(3):568-77. PubMed ID: 7935340
[TBL] [Abstract][Full Text] [Related]
7. Stereoselective hydroxylation of mexiletine in human liver microsomes: implication of P450IID6--a preliminary report.
Vandamme N; Broly F; Libersa C; Courseau C; Lhermitte M
J Cardiovasc Pharmacol; 1993 Jan; 21(1):77-83. PubMed ID: 7678683
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.
Nakamura K; Ariyoshi N; Yokoi T; Ohgiya S; Chida M; Nagashima K; Inoue K; Kodama T; Shimada N; Kamataki T
Biochem Biophys Res Commun; 2002 May; 293(3):969-73. PubMed ID: 12051754
[TBL] [Abstract][Full Text] [Related]
9. Functional evaluation of cytochrome P450 2D6 with Gly42Arg substitution expressed in Saccharomyces cerevisiae.
Tsuzuki D; Takemi C; Yamamoto S; Tamagake K; Imaoka S; Funae Y; Kataoka H; Shinoda S; Narimatsu S
Pharmacogenetics; 2001 Nov; 11(8):709-18. PubMed ID: 11692080
[TBL] [Abstract][Full Text] [Related]
10. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6.
Fukuda T; Nishida Y; Imaoka S; Hiroi T; Naohara M; Funae Y; Azuma J
Arch Biochem Biophys; 2000 Aug; 380(2):303-8. PubMed ID: 10933885
[TBL] [Abstract][Full Text] [Related]
11. Effect of 22 Novel Cytochrome P450 2D6 (CYP2D6) Variants Found in the Chinese Population on Hemangeol Metabolism In Vitro.
Liang B; Zhan Y; Huang X; Gu E; Dai D; Cai J; Hu G
Eur J Drug Metab Pharmacokinet; 2016 Dec; 41(6):759-765. PubMed ID: 26542054
[TBL] [Abstract][Full Text] [Related]
12. Assessment of 25 CYP2D6 alleles found in the Chinese population on propafenone metabolism in vitro.
Su Y; Liang BQ; Feng YL; Zhan Y; Gu E; Chen X; Dai DP; Hu GX; Cai JP
Can J Physiol Pharmacol; 2016 Aug; 94(8):895-9. PubMed ID: 27203132
[TBL] [Abstract][Full Text] [Related]
13. Metabolism of dexfenfluramine in human liver microsomes and by recombinant enzymes: role of CYP2D6 and 1A2.
Haritos VS; Ching MS; Ghabrial H; Gross AS; Taavitsainen P; Pelkonen O; Battaglia SE; Smallwood RA; Ahokas JT
Pharmacogenetics; 1998 Oct; 8(5):423-32. PubMed ID: 9825834
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of 50 CYP2D6 allelic variants by assessing primaquine 5-hydroxylation.
Saito T; Gutiérrez Rico EM; Kikuchi A; Kaneko A; Kumondai M; Akai F; Saigusa D; Oda A; Hirasawa N; Hiratsuka M
Drug Metab Pharmacokinet; 2018 Dec; 33(6):250-257. PubMed ID: 30366777
[TBL] [Abstract][Full Text] [Related]
15. Influence of the CYP2D6*10 allele on the metabolism of mexiletine by human liver microsomes.
Senda C; Yamaura Y; Kobayashi K; Fujii H; Minami H; Sasaki Y; Igarashi T; Chiba K
Br J Clin Pharmacol; 2001 Jul; 52(1):100-3. PubMed ID: 11453897
[TBL] [Abstract][Full Text] [Related]
16. Catalytic activities of human debrisoquine 4-hydroxylase cytochrome P450 (CYP2D6) expressed in yeast.
Ellis SW; Ching MS; Watson PF; Henderson CJ; Simula AP; Lennard MS; Tucker GT; Woods HF
Biochem Pharmacol; 1992 Aug; 44(4):617-20. PubMed ID: 1510710
[TBL] [Abstract][Full Text] [Related]
17. Role of cytochrome P450 2D6 genetic polymorphism in carvedilol hydroxylation in vitro.
Wang Z; Wang L; Xu RA; Zhan YY; Huang CK; Dai DP; Cai JP; Hu GX
Drug Des Devel Ther; 2016; 10():1909-16. PubMed ID: 27354764
[TBL] [Abstract][Full Text] [Related]
18. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function.
Oscarson M; Hidestrand M; Johansson I; Ingelman-Sundberg M
Mol Pharmacol; 1997 Dec; 52(6):1034-40. PubMed ID: 9415713
[TBL] [Abstract][Full Text] [Related]
19. Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine.
Marcucci KA; Pearce RE; Crespi C; Steimel DT; Leeder JS; Gaedigk A
Drug Metab Dispos; 2002 May; 30(5):595-601. PubMed ID: 11950793
[TBL] [Abstract][Full Text] [Related]
20. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes.
Yoshii K; Kobayashi K; Tsumuji M; Tani M; Shimada N; Chiba K
Life Sci; 2000; 67(2):175-84. PubMed ID: 10901285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
